CM
FATE icon

Crestline Management’s Fate Therapeutics FATE Stock Holding History

Crestline Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-24,174
Closed -$96K – 174
2017
Q3 		$96K Buy
+24,174
New +$82.2K 0.01% 120

Other funds holding FATE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Crestline Management's FATE Position: Q4 2017 in Review

Crestline Management sold out of Fate Therapeutics (FATE) in Q4 2017, closing a stake of 24,174 shares — an estimated $96K sold.

Crestline Management first reported a position in FATE in Q3 2017 and held it in 1 quarter. The position peaked at $96K in Q3 2017. 78 funds tracked by Wall St. Rank hold FATE as of Q4 2017.

  • Crestline Management reported no remaining Fate Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Crestline Management sold 24,174 Fate Therapeutics shares in Q4 2017, an estimated $96K.
  • Crestline Management first reported a position in Fate Therapeutics in Q3 2017 and held it in 1 quarter.
  • Crestline Management's Fate Therapeutics position peaked at $96K in Q3 2017.
  • 78 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2017.

Based on Crestline Management's 13F filing for Q4 2017, filed 14 Feb 2018.